Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
about
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeCurrent and emerging treatment options for patients with relapsed myelomaTreatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersSalvage second hematopoietic cell transplantation in myelomaDurable remission with salvage second autotransplants in patients with multiple myeloma.Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trialEfficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma.Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation.Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation.Current multiple myeloma treatment strategies with novel agents: a European perspectiveEvidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation.Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Relapsed multiple myeloma: who benefits from salvage autografts?Second autologous transplant as salvage therapy in multiple myeloma.Choosing treatment options for patients with relapsed/refractory multiple myeloma.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.Treatment of Relapsed/Refractory Multiple Myeloma.Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.Second auto-SCT for treatment of relapsed multiple myeloma.Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma.Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT.Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.When to recommend a second autograft in patients with relapsed myeloma?Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy.Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
P2860
Q26782868-54AF9BD9-822E-45F8-A5B1-CDF6640E7F6EQ26830878-A02076E2-9211-4CA5-B078-D6652EFC68B9Q26851202-1277335E-C32A-44FF-8E03-2D9B2D91A8F3Q30416452-6F5DD396-67B4-4038-969E-300A1C3CF08CQ33685400-EC6D66E1-F77A-48F6-8C35-C54E05A6B9D2Q36138646-71B847A0-9D90-4BBF-BE5D-B7EA37C314D0Q36612669-08315CB1-B716-4515-9840-B277A8D3EB62Q36834629-71AE01FC-9EE8-4A86-B41C-0D0DFB6CC809Q37627044-7FEC88A2-E815-4C45-A97F-6073B6539ECDQ37677935-CCD0EAF9-28F4-471B-9E34-27A76B12EF7AQ37829230-66F441ED-9047-4571-8A16-B6DAAE52C4D4Q37949201-7B51C310-05E0-4D6E-8219-32AA69A4C945Q38023515-330F5B48-9BA8-4EA6-8693-892C173D54F9Q38151157-CB264E4C-7AC6-4C5E-B3B3-FD618EB6B838Q38170453-0D14DE18-FD24-4050-94AE-0E3273CB4FEDQ38261677-BDABBEA8-27D0-4B76-AAF5-8EA5D6C88AFFQ38370539-F5451178-1A07-4423-B7C5-14D4AD623EB4Q38970597-6F2DFD87-7963-4ED3-AEED-AA373A06B88BQ44385832-9EB33782-0B27-4343-8FDB-125227D33C28Q44647283-BE654101-33E3-48A7-B018-383CFD0E287BQ44758991-F7C2FFEF-0DC0-400A-97A8-54A81E2261BFQ45918038-9881EE5C-32ED-472D-9D2B-3DD320A77729Q47149240-A81778B5-CE57-4BB9-82C4-DE401903B007Q47196540-B7941710-BB87-490B-B8EA-041346AE97D8Q48139344-8BAEDA85-4287-4668-80C8-F7F0061FE722Q48250743-FE74BA1C-B4F6-4406-B07C-47158A193457Q48921667-BF3A98DC-E9E8-4577-868B-1C3DA7B06FEBQ50438558-86BEEFDC-65A0-4AA4-A408-A7F1FFDBDE43Q53112373-A3FD568B-80A2-447C-A3FA-37B5C6A1F738
P2860
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
@en
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
@nl
type
label
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
@en
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
@nl
prefLabel
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
@en
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
@nl
P2093
P2860
P356
P1476
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
@en
P2093
D L Porter
D L Siegel
E A Stadtmauer
K Cunningham
P A Mangan
S J Schuster
P2860
P2888
P304
P356
10.1038/BMT.2008.334
P407
P577
2008-10-13T00:00:00Z
P5875
P6179
1021521647